LivaNova (NASDAQ:LIVN) Sets New 1-Year High – Here’s What Happened

Shares of LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $74.76 and last traded at $74.46, with a volume of 19139 shares traded. The stock had previously closed at $73.64.

Analyst Ratings Changes

A number of brokerages have issued reports on LIVN. Mizuho upped their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Robert W. Baird dropped their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Needham & Company LLC boosted their target price on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, Barclays boosted their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Trading Up 1.3%

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a market capitalization of $4.11 billion, a PE ratio of 38.34 and a beta of 0.82. The stock’s 50 day simple moving average is $65.57 and its two-hundred day simple moving average is $63.71.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts expect that LivaNova PLC will post 3.72 EPS for the current year.

Institutional Trading of LivaNova

A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC lifted its stake in shares of LivaNova by 17.3% during the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after buying an additional 514,268 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after buying an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of LivaNova by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after buying an additional 34,812 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of LivaNova by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after buying an additional 496,165 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.